Skip to main content
Unique mechanism of action
Navbar Image
Unique mechanism of action
This site is intended only for US healthcare professionals.

Unique mechanism of action

COSELA is the first and only transient IV CDK4/6 inihibitor1,3

  • COSELA acts in the bone marrow, where hematopoietic stem and progenitor cells give rise to multiple blood cell lineages1
  • When administered before chemotherapy, COSELA temporarily pauses these cells in the G1 phase of the cell cycle, reducing their vulnerability to cytotoxic injury1
  • After clearance of COSELA, hematopoietic stem and progenitor cells resume activity1,a
  • Based on its mechanism of action, COSELA can cause fetal harm when administered to a pregnant woman

CDK=cyclin-dependent kinase; ES-SCLC=extensive-stage small cell lung cancer; G1=growth phase 1; G2=growth phase 2; M=mitosis; pRb=phosphorylated retinoblastoma protein; Rb=retinoblastoma protein; S=DNA synthesis.

aEffect demonstrated in in vivo preclinical studies.